Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (3315)	6/18/2021 1:50:50 PM
From: CuttingEdge Bio	Respond to of 3557

The failures of Regeneron's commercial organization do not constitute scientific evidence of a difference between molecules. Sorry. It's an absurd argument. I have yet to see them move forward with an antibody that doesn't have industry standard optimal drug properties, while some companies definitely have (did you forget bococizumab? How about eculizumab dosed every other week IV? Commercial success depends on a lot of factors). But yeah, you can bet that Lag3 will be their first inferior antibody, I guess.